Nanosphere

Nanosphere

Founded 1999

Northbrook, United States 41 employees Post-IPO Debt Total: $125.07M Biotechnology, Health Care

Nanosphere is a biotechnology company founded in 1999 and headquartered in Northbrook, Illinois. The company is dedicated to enhancing medicine by providing targeted molecular diagnostic tests for earlier disease detection, optimal patient treatment, and improved healthcare economics. Its platform, the Verigene® System, allows clinicians to rapidly identify and treat bacteria and viruses responsible for complex, costly, and deadly infectious diseases. Nanosphere has a strong foundation in scientific discovery and innovation, holding over 175 patents based on technology developed at Northwestern University by Dr. Robert Letsinger and Dr. Chad Mirkin. In 2007, Nanosphere went public on NASDAQ (ticker symbol: NSPH), and since then, it has continued to focus on research and development. The company's test menu primarily targets infections of the bloodstream, respiratory tract, and gastrointestinal tract. Furthermore, Nanosphere attracted a $4.07M post-IPO debt investment on 29 May 2015. Nanosphere is now a part of the Luminex company. Overall, Nanosphere presents a compelling opportunity in the biotechnology and healthcare industries, leveraging its innovative technology and strong intellectual property portfolio. With its successful history of patents and public offering, Nanosphere demonstrates potential for long-term success, making it an intriguing prospect for venture capital investment.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	$4.07M	-		29 May 2015
Post IPO Equity	$30.20M	-		19 Sep 2013
Series D	$57.00M	3	Bain Capital, Allen & Company +1	16 May 2006
Series C	$5.00M	3	Takata Corporation, Nextgen Partners +1	06 Jan 2003
Series B	$5.40M	-		05 Mar 2001
Series A	$23.40M	-		05 Jan 2000

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Debt

$4.07M

29 May 2015

Post IPO Equity

$30.20M

19 Sep 2013

Series D

$57.00M

Bain Capital, Allen & Company +1

16 May 2006

Series C

$5.00M

Takata Corporation, Nextgen Partners +1

06 Jan 2003

Series B

$5.40M

05 Mar 2001

Series A

$23.40M

05 Jan 2000

FAQ About Nanosphere

Nanosphere is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. Nanosphere’s platform, the Verigene® System, enables clinicians to rapidly identify and treat the...

Nanosphere was founded in 1999.

Nanosphere is headquartered in Northbrook, United States.

Nanosphere operates in Biotechnology and Health Care. Its work centres on molecular diagnostics, nanotechnology, clinical diagnostic tests and genetic variations.

Nanosphere has approximately 41 employees.

Nanosphere has completed 6 funding rounds, raising a total of $125.07M. The latest funding stage is Post-IPO Debt.

Top alternatives and competitors to Nanosphere include Zymeron Corporation, Quidel, Mobidiag, A Hologic Company, First Light Diagnostics, Linear Diagnostics Limited. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Nanosphere and Zymeron Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Nanosphere

Funding Rounds & Investors (6)

Nanosphere Alternatives & Competitors

FAQ About Nanosphere